Skip to content
10-K

Annual Report

CHINA GEWANG BIOTECHNOLOGY, INC.

0001213900-17-001201

← back to feed
Filed
Feb 10, 2017 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2016 · Feb 10, 2017 75M sh
Operating Cash Flow FY 2016 · Nov 30, 2016 −$2.84M
Operating Cash Flow FY 2016 · Nov 30, 2015 $1.04M
Operating Cash Flow FY 2016 · Nov 30, 2014 $728.9K
Cash And Equivalents FY 2016 · Nov 30, 2016 $13.11M
Cash And Equivalents FY 2016 · Nov 30, 2015 $8.67M
Cash And Equivalents FY 2016 · Nov 30, 2014 $3.01M
Cash And Equivalents FY 2016 · Nov 30, 2013 $2.29M
Stockholders Equity FY 2016 · Nov 30, 2016 $31.13M
Stockholders Equity FY 2016 · Nov 30, 2015 $8.87M
Current Liabilities FY 2016 · Nov 30, 2016 $4.82M
Current Liabilities FY 2016 · Nov 30, 2015 $405.35K
Current Assets FY 2016 · Nov 30, 2016 $29.96M
Current Assets FY 2016 · Nov 30, 2015 $9.3M
Total Assets FY 2016 · Nov 30, 2016 $36.2M
Total Assets FY 2016 · Nov 30, 2015 $9.36M
Eps Basic FY 2016 · Nov 30, 2016 $0.20
Eps Basic FY 2016 · Nov 30, 2015 $0.03
Eps Basic FY 2016 · Nov 30, 2014 $0.02
Sga Expense FY 2016 · Nov 30, 2016 $1.01M
Sga Expense FY 2016 · Nov 30, 2015 $528.63K
Sga Expense FY 2016 · Nov 30, 2014 $150.15K
Rd Expense FY 2016 · Nov 30, 2016 $605.82K
Net Income FY 2016 · Nov 30, 2016 $13.57M
Net Income FY 2016 · Nov 30, 2015 $1.19M
Net Income restated FY 2016 · Nov 30, 2014 $784.15K
Operating Income FY 2016 · Nov 30, 2016 $12.1M
Operating Income FY 2016 · Nov 30, 2015 $1.63M
Operating Income FY 2016 · Nov 30, 2014 $1.02M
Gross Profit FY 2016 · Nov 30, 2016 $16.75M
Gross Profit FY 2016 · Nov 30, 2015 $3M
Gross Profit FY 2016 · Nov 30, 2014 $1.64M
Cost Of Revenue FY 2016 · Nov 30, 2016 $28.77M
Cost Of Revenue restated FY 2016 · Nov 30, 2015 $1.19M
Cost Of Revenue restated FY 2016 · Nov 30, 2014 $725.45K
Revenue FY 2016 · Nov 30, 2016 $45.52M
Revenue FY 2016 · Nov 30, 2015 $4.18M
Revenue restated FY 2016 · Nov 30, 2014 $45.52M